Business Description
Coherus BioSciences Inc
NAICS : 541714
SIC : 2836
ISIN : US19249H1032
Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.36 | |||||
| Equity-to-Asset | -0.17 | |||||
| Debt-to-Equity | -3.07 | |||||
| Debt-to-EBITDA | 7.24 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3 | |||||
| Beneish M-Score | -3.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -21.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 50.21 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.73 | |||||
| 9-Day RSI | 61.83 | |||||
| 14-Day RSI | 63.6 | |||||
| 3-1 Month Momentum % | -40.1 | |||||
| 6-1 Month Momentum % | -56.25 | |||||
| 12-1 Month Momentum % | -67.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.33 | |||||
| Days Inventory | 130.66 | |||||
| Days Sales Outstanding | 264.81 | |||||
| Days Payable | 90.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.7 | |||||
| Shareholder Yield % | 59.49 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.71 | |||||
| Operating Margin % | -45.45 | |||||
| Net Margin % | -0.15 | |||||
| FCF Margin % | -20.38 | |||||
| ROA % | -0.07 | |||||
| ROIC % | -63.8 | |||||
| 3-Year ROIIC % | -1509.14 | |||||
| ROC (Joel Greenblatt) % | 119.17 | |||||
| ROCE % | 12.41 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 17.62 | |||||
| PS Ratio | 0.59 | |||||
| EV-to-EBIT | 10.79 | |||||
| EV-to-Forward-EBIT | 5.95 | |||||
| EV-to-EBITDA | 9.25 | |||||
| EV-to-Forward-EBITDA | 5.89 | |||||
| EV-to-Revenue | 1.13 | |||||
| EV-to-Forward-Revenue | 2.08 | |||||
| EV-to-FCF | -5.56 | |||||
| Price-to-GF-Value | 0.35 | |||||
| Earnings Yield (Greenblatt) % | 9.27 | |||||
| FCF Yield % | -33.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CHRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coherus BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 304.34 | ||
| EPS (TTM) ($) | -0.08 | ||
| Beta | 1.09 | ||
| 3-Year Sharpe Ratio | -0.74 | ||
| 3-Year Sortino Ratio | -1 | ||
| Volatility % | 107.54 | ||
| 14-Day RSI | 63.6 | ||
| 14-Day ATR ($) | 0.190645 | ||
| 20-Day SMA ($) | 1.33384 | ||
| 12-1 Month Momentum % | -67.14 | ||
| 52-Week Range ($) | 0.6603 - 3.7 | ||
| Shares Outstanding (Mil) | 115.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coherus BioSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coherus BioSciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Coherus BioSciences Inc Frequently Asked Questions
What is Coherus BioSciences Inc(CHRS)'s stock price today?
The current price of CHRS is $1.61. The 52 week high of CHRS is $3.70 and 52 week low is $0.66.
When is next earnings date of Coherus BioSciences Inc(CHRS)?
The next earnings date of Coherus BioSciences Inc(CHRS) is 2025-03-13 Est..
Does Coherus BioSciences Inc(CHRS) pay dividends? If so, how much?
Coherus BioSciences Inc(CHRS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers